DXL702

DXL702 is a monoclonal antibody being developed for the treatment of metastatic breast cancer. The antibody is designed to bind to HER2, a protein receptor over-expressed on breast cancer cells. Current antibody therapy is only effective in cancers with over expressed HER2. Results from proof-of-principle animal experiments established the superiority of DXL702 over Herceptin to arrest growth of tumor cell implants in immunocompromised mice. The tumor line chosen was one with low expression of the HER2 target antigen and this result provides further evidence that DXL702 can kill tumors that may evade existing treatment because of low expression of the intended target at lower doses than commercially available anti-her2/neu antibodies. As predicted from in vitro studies evaluating the efficacy of DXL702 on low expression cell lines, DXL technology has been confirmed to enable better killing of low expression cancer cells in vivo.